These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22517703)

  • 1. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
    Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
    J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
    Milani P; Palladini G; Merlini G
    Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.
    Avivi I; Cohen YC; Joffe E; Benyamini N; Held-Kuznetsov V; Trestman S; Terpos E; Dimopoulos MA; Kastritis E
    Hematol Oncol; 2017 Dec; 35(4):734-740. PubMed ID: 27641057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
    Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
    Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
    Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
    Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.
    Palladini G; Jaccard A; Milani P; Lavergne D; Foli A; Bender S; Lavatelli F; Bosoni T; Valentini V; Pirolini L; Ferraro G; Basset M; Russo F; Nuvolone M; Albertini R; Cogne M; Merlini G
    Clin Chem Lab Med; 2017 Oct; 55(11):1734-1743. PubMed ID: 28343171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
    Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
    J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin free light chains and solitary plasmacytoma of bone.
    Dingli D; Kyle RA; Rajkumar SV; Nowakowski GS; Larson DR; Bida JP; Gertz MA; Therneau TM; Melton LJ; Dispenzieri A; Katzmann JA
    Blood; 2006 Sep; 108(6):1979-83. PubMed ID: 16741249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.
    Kumar S; Zhang L; Dispenzieri A; Van Wier S; Katzmann JA; Snyder M; Blood E; DeGoey R; Henderson K; Kyle RA; Bradwell AR; Greipp PR; Rajkumar SV; Fonseca R
    Leukemia; 2010 Aug; 24(8):1498-505. PubMed ID: 20520636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
    Dispenzieri A; Lacy MQ; Katzmann JA; Rajkumar SV; Abraham RS; Hayman SR; Kumar SK; Clark R; Kyle RA; Litzow MR; Inwards DJ; Ansell SM; Micallef IM; Porrata LF; Elliott MA; Johnston PB; Greipp PR; Witzig TE; Zeldenrust SR; Russell SJ; Gastineau D; Gertz MA
    Blood; 2006 Apr; 107(8):3378-83. PubMed ID: 16397135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
    Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
    Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
    Ermak N; Nguyen-Khoa T; Alyanakian MA
    Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.